Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986325 in Healthy Japanese Participants
NCT05813717Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986325 in primary Sjögren's syndrome (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with Adverse events, Number of participants with clinical laboratory abnormalities and 3 more. Started Apr 2023; status: completed.
02
Drugs
BMS-986325
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT05813717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813717.